Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
This study that aims to evaluate the addition of MPDL3280A (atezolizumab) to carboplatin and nab-paclitaxel in patients with early high-risk and locally advanced triple negative breast cancer. compared to the control arm of carboplatin and abraxane. Half of participants will receive MPDL3280A in combination with carboplatin and abraxane, while the other half will receive only carboplatin and abraxane.
Epistemonikos ID: f8d391183dbe0bcec27dec0d9ba0b96ccfadd34a
First added on: May 12, 2024